Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension (WAVE_IV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02029885
Recruitment Status : Unknown
Verified January 2016 by Kona Medical Inc..
Recruitment status was:  Recruiting
First Posted : January 8, 2014
Last Update Posted : January 8, 2016
Sponsor:
Information provided by (Responsible Party):
Kona Medical Inc.

Tracking Information
First Submitted Date  ICMJE January 6, 2014
First Posted Date  ICMJE January 8, 2014
Last Update Posted Date January 8, 2016
Study Start Date  ICMJE August 2014
Estimated Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 11, 2014)
  • Safety at 6 weeks follow-up [ Time Frame: 6 weeks ]
    Safety will be assessed by incidence of Major Adverse Events (MAE), defined as a composite of the following events at 6-weeks follow-up.
    • All cause mortality;
    • End-stage Renal Disease defined as eGFR < 15 ml/min or need for renal replacement therapy
    • Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications as assessed by toxicological and other medical analyses and testing.
    OR - New renal artery stenosis > 70% confirmed by angiography within 6 months of randomization
  • Change in OBP [ Time Frame: 6 months ]
    Change in Office Systolic Blood Pressure (OBP) as measured from screening visit one to the 6 month post randomization follow-up visit.
Original Primary Outcome Measures  ICMJE
 (submitted: January 6, 2014)
Safety at 3 weeks follow-up [ Time Frame: 3 weeks ]
Safety will be assessed by incidence of Major Adverse Events (MAE), defined as a composite of the following events at 3-weeks follow-up.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 11, 2014)
Change in ABPM [ Time Frame: 6 months ]
Change in average 24-hour ambulatory blood pressure from screening to the 6 month follow-up visit
Original Secondary Outcome Measures  ICMJE
 (submitted: January 6, 2014)
Efficacy [ Time Frame: 24 months ]
Long term performance (efficacy) is evaluated by comparing the change in Office Systolic blood pressure from screening through the 24-month evaluation
Current Other Pre-specified Outcome Measures
 (submitted: June 11, 2014)
  • Chronic Safety [ Time Frame: 6 months ]
    Chronic safety is assessed and compared between the control and treatment groups at 6 months post-randomization as follows:
    • Cardiovascular/Renal Death;
    • End stage Renal Disease
    • Increase in serum creatinine of > 50%; and
    • Hospitalization for hypertensive crisis not confirmed non-adherence with medications.
  • Reduction in blood pressure [ Time Frame: 6 months ]
    Reduction in systolic and diastolic blood pressure as compared between groups at time points through the 6 month follow-up period for interval differences of 10,15 and 20 mmHg.
  • Incidence of achieving target OBP [ Time Frame: 6 months ]
    Incidence of achieving target OBP (< 140 mmHg) through the 6 month follow-up period.
  • Reduction in anti-hypertensive medications [ Time Frame: 6 months ]
    Incidence of reductions in the number of anti-hypertensive medications and reductions in the doses of anti-hypertensive medications.
  • Changes in OBP [ Time Frame: 24 months ]
    Changes in OBP from screening to the 12, 18, and 24 month follow-up periods.
  • Changes in HR [ Time Frame: 6 months ]
    Changes in HR (as measured by OBP and ABPM) through the 6 month follow-up period.
Original Other Pre-specified Outcome Measures
 (submitted: January 6, 2014)
Long term Safety [ Time Frame: 24 months ]
Chronic safety is assessed by incidence and evaluation by any serious adverse events associated with the Kona Medical Surround Sound non-invasive system through the 24 week follow-up period
 
Descriptive Information
Brief Title  ICMJE Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension
Official Title  ICMJE Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension
Brief Summary To demonstrate that non-invasive renal denervation is safe and shows a net difference in blood pressure reduction when compared to sham in subjects with uncontrolled hypertension.
Detailed Description This study is a sham controlled, double blind study of subjects with uncontrolled hypertension consisting of two arms, sham and therapy. Bilateral renal denervation will be performed non-invasively using the Kona Medical Surround Sound System which delivers focused ultrasound therapy to ablate the nerves surrounding the renal artery utilizing real time ultrasound for targeting and tracking.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Hypertension
Intervention  ICMJE
  • Device: Investigational Therapy (Surround Sound)
  • Device: Sham Control
Study Arms  ICMJE
  • Experimental: Investigational Therapy (Surround Sound)
    Investigational Therapy using external focused ultrasound
    Intervention: Device: Investigational Therapy (Surround Sound)
  • Sham Comparator: Sham Control
    Blinded Sham Control Arm
    Intervention: Device: Sham Control
Publications * Saxena M, Shour T, Shah M, Wolff CB, Julu POO, Kapil V, Collier DJ, Ng FL, Gupta A, Balawon A, Pheby J, Zak A, Rull G, O'Brien B, Schmieder RE, Lobo MD. Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. J Am Heart Assoc. 2018 Jun 12;7(12). pii: e009151. doi: 10.1161/JAHA.118.009151.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: September 23, 2014)
132
Original Estimated Enrollment  ICMJE
 (submitted: January 6, 2014)
50
Estimated Study Completion Date  ICMJE March 2018
Estimated Primary Completion Date March 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject is at least 18 years of age and no more than 90 years of age
  2. Average SBP ≥ 160 mmHg
  3. 24 hour average ABPM daytime SBP ≥ 135 mmHg.
  4. No medication changes for a minimum of 1 months prior to screening.
  5. At minimum, subject must be on at least three antihypertensive medications, with one being a diuretic, and each must meet one or more of the following full dose criteria:

    1. Highest labeled dose according to medication's labeling;
    2. Highest usual dose per clinical guidelines JNC-7;
    3. Highest tolerated dose; and/or
    4. Highest appropriate dose for the subject per the PI's clinical judgment.
  6. Subject has two functioning kidneys.
  7. Subject has an eGFR value of ≥ 30 ml/min/1.73 m² (MDRD formula).

Exclusion Criteria:

  1. Subject has any secondary cause of hypertension
  2. Subject has evidence of clinically significant renal artery stenosis as determined by flow rate, velocity and Doppler analysis on ultrasound
  3. Subject has kidney stones that are of a size and location that are determined at discretion of the investigator to potentially interfere with treatment
  4. Subject has a history of intra-abdominal surgery within the past six months
  5. Subject has heterogeneities in the kidney such as large cysts or tumors that are determined at discretion of the investigator to potentially interfere with treatment.
  6. Stenotic valvular heart disease for which BP reduction would be hazardous as determined by referring physician.
  7. MI, unstable angina, or CVA in the prior 6 months.
  8. Known severe primary pulmonary HTN
  9. Subject has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
  10. Subject has hemodynamically significant valvular heart disease.
  11. Subject has BMI over 40 km/m^2
  12. Subject has a target treatment depth over 13 cm.
  13. Subject has anatomy that precludes treatment with the Kona Medical Surround Sound System.
  14. Subject is pregnant, nursing, or intends to become pregnant during the trial period.
  15. Subject is currently enrolled in other potentially confounding research.
  16. Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
  17. Subject is unable, or unwilling, to comply with the protocol-required follow-up schedule
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Colombia,   Czech Republic,   Germany,   New Zealand,   Poland,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02029885
Other Study ID Numbers  ICMJE KM14-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Kona Medical Inc.
Study Sponsor  ICMJE Kona Medical Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Roland Schmieder, MD University Hospital of University of Erlangen-Nuremberg
PRS Account Kona Medical Inc.
Verification Date January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP